{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:58:56Z","timestamp":1783720736905,"version":"3.55.0"},"reference-count":106,"publisher":"Termedia Sp. z.o.o.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BioTechnologia"],"abstract":"<jats:p>Nanotechnology presents an exciting opportunity in cancer research by offering significant advancements in therapies, diagnosis, and management. It possesses unparalleled potential to enhance the accuracy and effectiveness of cancer therapy while simultaneously reducing adverse effects, owing to its distinctive capability to manipulate matter at a molecular level. Using nanoparticle carriers has facilitated the precise administration of therapeutic agents to afflicted areas within the human body through customized drug delivery systems, resulting in improved treatment accuracy and efficacy while reducing adverse effects. These techniques improve drug solubility and stability, leading to elevated levels of biochemical availability and improved efficacy outcomes for patients with minimal negative effects during treatment cycles. Another use case for nanoparticles includes tumor imaging; functionalized with targeting ligands containing diagnostic agents, they foster early detection, making quicker remedial action plans possible. Overall, the incorporation of nanotechnology ensures a promising future, although it stresses the need to address regulatory hurdles and safety concerns before widespread clinical implementation. Despite the complexity of cancer research and patient care, nanotechnology shows promise in transforming both fields.<\/jats:p>","DOI":"10.5114\/bta.2024.141807","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T07:08:10Z","timestamp":1727680090000},"page":"287-303","source":"Crossref","is-referenced-by-count":13,"title":["Nanotechnology in cancer therapeutics, diagnosis,\nand management"],"prefix":"10.5114","volume":"105","author":[{"given":"Disha","family":"Hazarika","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Shankarishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"ref-1360928","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00280-014-2498-5","article-title":"A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer","volume":"74","author":"Ahn H.K","year":"2014","unstructured":"Ahn H.K., Jung M., Sym S.J., Shin D.B., Kang S.M., Kyung S.Y., Park J.W., Jeong S.H., Cho E.K. (2014) A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 74: 277\u2013282.","journal-title":"Cancer Chemother. Pharmacol"},{"issue":"1","key":"ref-1360929","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen T.M","year":"2013","unstructured":"Allen T.M., Cullis P.R. (2013) Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65(1): 36\u201348.","journal-title":"Adv. Drug Deliv. Rev"},{"issue":"1054","key":"ref-1360930","doi-asserted-by":"crossref","first-page":"20150207","DOI":"10.1259\/bjr.20150207","article-title":"Applications of nanoparticles for diagnosis and therapy of cancer","volume":"88","author":"Baetke S.C","year":"2015","unstructured":"Baetke S.C., Lammers T., Kiessling F. (2015) Applications of nanoparticles for diagnosis and therapy of cancer. Br. J. Radiol. 88(1054): 20150207.","journal-title":"Br. J. Radiol"},{"issue":"3","key":"ref-1360931","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/annonc\/mdt543","article-title":"Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer","volume":"25","author":"Baselga J","year":"2014","unstructured":"Baselga J., Manikhas A., Cort\u00e9s J., Llombart A., Roman L., Semiglazov V.F., et al. (2014) Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann. Oncol. 25(3): 592\u2013598.","journal-title":"Ann. Oncol"},{"issue":"6","key":"ref-1360932","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3892\/mco.2014.356","article-title":"Passive targeting of nanoparticles to cancer: A comprehensive review of the literature","volume":"2","author":"Bazak R","year":"2014","unstructured":"Bazak R., Houri M., El Achy S., Hussein W., Refaat T. (2014) Passive targeting of nanoparticles to cancer: A comprehensive review of the literature. Mol. Clin. Oncol. 2(6): 904\u2013908.","journal-title":"Mol. Clin. Oncol"},{"issue":"3","key":"ref-1360933","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1039\/C3CS60273G","article-title":"Chemical modifications and bioconjugate reactions of nanomaterials for sensing, imaging, drug delivery and therapy","volume":"43","author":"Biju V","year":"2014","unstructured":"Biju V. (2014) Chemical modifications and bioconjugate reactions of nanomaterials for sensing, imaging, drug delivery and therapy. Chem. Soc. Rev. 43(3): 744\u2013764.","journal-title":"Chem. Soc. Rev"},{"issue":"8","key":"ref-1360934","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","article-title":"NBTXR3, a first-in-class radio-enhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act. In. Sarc): a multicentre, phase 2\u20133, randomized, controlled trial","volume":"20","author":"Bonvalot S","year":"2019","unstructured":"Bonvalot S., Rutkowski P.L., Thariat J., Carr\u00e8re S., Ducassou A., Sunyach M.P., Agoston P., Hong A., Mervoyer A., Rastrelli M., Moreno V. (2019) NBTXR3, a first-in-class radio-enhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act. In. Sarc): a multicentre, phase 2\u20133, randomized, controlled trial. Lancet Oncol. 20(8): 1148\u20131159.","journal-title":"Lancet Oncol"},{"issue":"37","key":"ref-1360935","doi-asserted-by":"crossref","first-page":"12692","DOI":"10.1039\/C7DT02139A","article-title":"Folic acid on iron oxide nanoparticles: platform with high potential for simultaneous targeting, MRI detection and hyperthermia treatment of lymph node metastases of prostate cancer","volume":"46","author":"Bonvin D","year":"2017","unstructured":"Bonvin D., Bastiaansen J.A., Stuber M., Hofmann H., Ebersold M.M. (2017) Folic acid on iron oxide nanoparticles: platform with high potential for simultaneous targeting, MRI detection and hyperthermia treatment of lymph node metastases of prostate cancer. Dalton Trans. 46(37): 12692\u201312704.","journal-title":"Dalton Trans"},{"key":"ref-1360936","first-page":"306","article-title":"Gold nanoparticles-enhanced MRI: A systematic review","volume":"469","author":"Cai J","year":"2019","unstructured":"Cai J., Li Z., Huang J., Liu X., Xing J. (2019) Gold nanoparticles-enhanced MRI: A systematic review. J. Magnetism Magnetic Mater. 469: 306\u2013313.","journal-title":"J. Magnetism Magnetic Mater"},{"key":"ref-1360937","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1158\/0008-5472.CAN-11-3368","article-title":"Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule","volume":"72","author":"Castro J.E","year":"2012","unstructured":"Castro J.E., Melo-Cardenas J., Urquiza M., Barajas-Gamboa J.S., Pakbaz R.S., Kipps T.J. (2012) Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. Cancer Res. 72: 2937\u20132948.","journal-title":"Cancer Res"},{"issue":"22","key":"ref-1360938","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1002\/smll.201401309","article-title":"Structural DNA nanotechnology for intelligent drug delivery","volume":"10","author":"Chao J","year":"2014","unstructured":"Chao J., Liu H., Su S., Wang L., Huang W., Fan C. (2014) Structural DNA nanotechnology for intelligent drug delivery. Small. 10(22): 4626\u20134635.","journal-title":"Small"},{"issue":"1","key":"ref-1360939","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi M","year":"2023","unstructured":"Chehelgerdi M., Chehelgerdi M., Allela O.Q., Pecho R.D., Jayasankar N., Rao DP., Thamaraikani T., Vasanthan M., Viktor P., Lakshmaiya N., et al. (2023) Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol. Cancer 22(1): 169.","journal-title":"Mol. Cancer"},{"issue":"10","key":"ref-1360940","doi-asserted-by":"crossref","first-page":"1802228","DOI":"10.1002\/adma.201802228","article-title":"Nanoparticle enhanced radiotherapy to trigger robust cancer immunotherapy","volume":"31","author":"Chen Q","year":"2019","unstructured":"Chen Q., Chen J., Yang Z., Xu J., Xu L., Liang C., Han X., Liu Z. (2019) Nanoparticle enhanced radiotherapy to trigger robust cancer immunotherapy. Adv. Mater. 31(10): 1802228.","journal-title":"Adv. Mater"},{"issue":"9","key":"ref-1360941","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nnano.2015.195","article-title":"DNA nanotechnology from the test tube to the cell","volume":"10","author":"Chen Y.J","year":"2015","unstructured":"Chen Y.J., Groves B., Muscat R.A., Seelig G. (2015) DNA nanotechnology from the test tube to the cell. Nat. Nanotechnol. 10(9): 748\u2013760.","journal-title":"Nat. Nanotechnol"},{"issue":"9","key":"ref-1360942","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3390\/biom12091198","article-title":"Biosensor-integrated drug delivery systems as new materials for biomedical applications","volume":"12","author":"Cicha I","year":"2022","unstructured":"Cicha I., Priefer R., Severino P., Souto E.B., Jain S. (2022) Biosensor-integrated drug delivery systems as new materials for biomedical applications. Biomolecules 12(9): 1198.","journal-title":"Biomolecules"},{"issue":"1","key":"ref-1360943","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-022-01361-w","article-title":"Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk\/secondary AML: post hoc analysis of a randomized, phase 3 trial","volume":"15","author":"Cortes J.E","year":"2022","unstructured":"Cortes J.E, Lin T.L, Asubonteng K., Faderl S., Lancet J.E., Prebet T. (2022) Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk\/secondary AML: post hoc analysis of a randomized, phase 3 trial. J. Hematol. Oncol. 15(1): 155.","journal-title":"J. Hematol. Oncol"},{"key":"ref-1360944","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.2147\/IJN.S378074","article-title":"Nanotechnology: a promising approach for cancer diagnosis, therapeutics, and theragnosis","volume":"17","author":"Dessale M","year":"2022","unstructured":"Dessale M., Mengistu G., Mengist H.M. (2022) Nanotechnology: a promising approach for cancer diagnosis, therapeutics, and theragnosis. Int. J. Nanomed. 17: 3735.","journal-title":"Int. J. Nanomed"},{"issue":"2","key":"ref-1360945","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nano.2012.05.015","article-title":"Effect of ligand density, receptor density, and nanoparticle size on cell targeting","volume":"9","author":"Elias D.R","year":"2013","unstructured":"Elias D.R., Poloukhtine A., Popik V., Tsourkas A. (2013) Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomed. Nanotechnol. Biol. Med. 9(2): 194\u2013201.","journal-title":"Nanomed. Nanotechnol. Biol. Med"},{"issue":"5","key":"ref-1360946","first-page":"50","article-title":"FDA approves DaunoXome as first-line therapy for Kaposi\u2019s sarcoma","volume":"2","author":"FDA U","year":"1996","unstructured":"FDA U (1996) FDA approves DaunoXome as first-line therapy for Kaposi\u2019s sarcoma. Food and Drug Administration. J. Int. Assoc. Physicians AIDS Care. 2(5): 50\u201351.","journal-title":"Food and Drug Administration. J. Int. Assoc. Physicians AIDS Care"},{"issue":"7","key":"ref-1360947","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.3390\/ijms24076615","article-title":"Liposomes in cancer therapy: how did we start and where are we now","volume":"24","author":"Fulton M.D","year":"2023","unstructured":"Fulton M.D., Najahi-Missaoui W. (2023) Liposomes in cancer therapy: how did we start and where are we now. Int. J. Mol. Sci. 24(7): 6615.","journal-title":"Int. J. Mol. Sci"},{"issue":"43","key":"ref-1360948","first-page":"6909","article-title":"Gold nanorods and their plasmonic properties in biological applications","volume":"6","author":"Gao F","year":"2018","unstructured":"Gao F., Huo D., Zhang Y., Li Y., Li Y. (2018) Gold nanorods and their plasmonic properties in biological applications. J. Mater. Chem. B 6(43): 6909\u20136920.","journal-title":"J. Mater. Chem. B"},{"issue":"4","key":"ref-1360949","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1200\/JCO.1995.13.4.996","article-title":"Phase I\/II clinical and pharmacokinetic evaluation of liposomal daunorubicin","volume":"13","author":"Gill P.S","year":"1995","unstructured":"Gill P.S., Espina B.M., Muggia F., Cabriales S., Tulpule A., Esplin J.A., Liebman H.A., Forssen E., Ross M.E., Levine A.M. (1995) Phase I\/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J. Clin. Oncol. 13(4): 996\u20131003.","journal-title":"J. Clin. Oncol"},{"issue":"12","key":"ref-1360950","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1158\/1055-9965.EPI-20-0075","article-title":"Radiomics improves cancer screening and early detection","volume":"29","author":"Gillies R.J","year":"2020","unstructured":"Gillies R.J., Schabath M.B. (2020) Radiomics improves cancer screening and early detection. Cancer Epidemiol. Biomark. Prevent. 29(12): 2556\u20132567.","journal-title":"Cancer Epidemiol. Biomark. Prevent"},{"key":"ref-1360951","doi-asserted-by":"crossref","first-page":"115751","DOI":"10.1016\/j.jpba.2023.115751","article-title":"Liposomes characterization for market approval as pharmaceutical products: Analytical methods, guidelines, and standardized protocols","volume":"236","author":"Giordani S","year":"2023","unstructured":"Giordani S., Marassi V., Zattoni A., Roda B., Reschiglian P. (2023) Liposomes characterization for market approval as pharmaceutical products: Analytical methods, guidelines, and standardized protocols. J. Pharm. Biomed. Anal. 236: 115751.","journal-title":"J. Pharm. Biomed. Anal"},{"issue":"2","key":"ref-1360952","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/2472630318816668","article-title":"siRNA-conjugated nanoparticles to treat ovarian cancer","volume":"24","author":"Halbur C","year":"2019","unstructured":"Halbur C., Choudhury N., Chen M., Kim J.H., Chung E.J. (2019) siRNA-conjugated nanoparticles to treat ovarian cancer. Slas Technol. 24(2): 137\u2013150.","journal-title":"Slas Technol"},{"issue":"3","key":"ref-1360953","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1039\/C8NR07769J","article-title":"Applications of nanoparticles in biomedical imaging","volume":"11","author":"Han X","year":"2019","unstructured":"Han X., Xu K., Taratula O., Farsad K. (2019) Applications of nanoparticles in biomedical imaging. Nanoscale 11(3): 799\u2013819.","journal-title":"Nanoscale"},{"key":"ref-1360954","doi-asserted-by":"crossref","first-page":"119195","DOI":"10.1016\/j.biomaterials.2019.05.006","article-title":"Hypoxia-targeting dendritic MRI contrast agent based on internally hydroxy dendrimer for tumor imaging","volume":"213","author":"Han Y","year":"2019","unstructured":"Han Y., Zhou X., Qian Y., Hu H., Zhou Z., Liu X., Tang J., Shen Y. (2019) Hypoxia-targeting dendritic MRI contrast agent based on internally hydroxy dendrimer for tumor imaging. Biomaterials 213: 119195.","journal-title":"Biomaterials"},{"key":"ref-1360955","first-page":"46","article-title":"Gold nanoparticles for biomedical applications: recent advances and future prospects","volume":"123","author":"Hao S","year":"2021","unstructured":"Hao S., Yuan L., Zhang L., Huang Y., Tang X., Feng X. (2021) Gold nanoparticles for biomedical applications: recent advances and future prospects. Acta Biomater. 123: 46\u201365.","journal-title":"Acta Biomater"},{"issue":"128","key":"ref-1360956","doi-asserted-by":"crossref","first-page":"128ra39","DOI":"10.1126\/scitranslmed.3003651","article-title":"Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile","volume":"4","author":"Hrkach J","year":"2012","unstructured":"Hrkach J., Von Hoff D., Ali M.M., Andrianova E., Auer J., Campbell T., et al. (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4(128): 128ra39.","journal-title":"Sci. Transl. Med"},{"issue":"2","key":"ref-1360957","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/jpm11020124","article-title":"Nanodrug delivery systems modulate tumor vessels to increase the enhanced permeability and retention effect","volume":"11","author":"Huang D","year":"2021","unstructured":"Huang D., Sun L., Huang L., Chen Y. (2021) Nanodrug delivery systems modulate tumor vessels to increase the enhanced permeability and retention effect. J. Pers. Med. 11(2): 124.","journal-title":"J. Pers. Med"},{"issue":"1","key":"ref-1360958","first-page":"1","article-title":"Nanomedicine: reshaping clinical practice","volume":"19","author":"Huang P","year":"2021","unstructured":"Huang P., Lin J., Li W., Rong P., Wang Z., Wang S., et al. (2021) Nanomedicine: reshaping clinical practice. J. Nanobiotechnol. 19(1): 1\u201317.","journal-title":"J. Nanobiotechnol"},{"issue":"1","key":"ref-1360959","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7150\/ntno.18216","article-title":"Gold nanoparticle-based platforms for circulating cancer marker detection","volume":"1","author":"Huang X","year":"2017","unstructured":"Huang X., O\u2019Connor R., Kwizera E.A. (2017) Gold nanoparticle-based platforms for circulating cancer marker detection. Nanotheranostics 1(1): 80.","journal-title":"Nanotheranostics"},{"issue":"3","key":"ref-1360960","first-page":"782","article-title":"The EPR effect for drug delivery to solid tumors: A challenge resolved?","volume":"172","author":"Jain R.K","year":"2013","unstructured":"Jain R.K. (2013) The EPR effect for drug delivery to solid tumors: A challenge resolved? J. Control. Release 172(3): 782\u2013794.","journal-title":"J. Control. Release"},{"issue":"18","key":"ref-1360961","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.7150\/ijms.49801","article-title":"Application of nanotechnology in cancer diagnosis and therapy-a mini-review","volume":"17","author":"Jin C","year":"2020","unstructured":"Jin C., Wang K., Oppong-Gyebi A., Hu J. (2020) Application of nanotechnology in cancer diagnosis and therapy-a mini-review. Int. J. Med. Sci. 17(18): 2964.","journal-title":"Int. J. Med. Sci"},{"key":"ref-1360962","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3109\/02656731003745740","article-title":"Magnetic nanoparticle hyperthermia for prostate cancer","volume":"26","author":"Johannsen M","year":"2010","unstructured":"Johannsen M., Thiesen B., Wust P., Jordan A., Loening S. (2010) Magnetic nanoparticle hyperthermia for prostate cancer. Int. J. Hyperther. 26: 790\u2013795.","journal-title":"Int. J. Hyperther"},{"key":"ref-1360963","volume-title":"Polymeric nanoparticles as promising tool for anti-cancer therapeutics","author":"Kesharwani P","year":"2019","unstructured":"Kesharwani P., Paknikar K.M., Gajbhiye V. (2019) Polymeric nanoparticles as promising tool for anti-cancer therapeutics. Academic Press. ISBN 9780128169636"},{"key":"ref-1360964","doi-asserted-by":"crossref","first-page":"ix3","DOI":"10.1093\/annonc\/mdy426.010","article-title":"Multicenter trial for safety and toxicity of a nanoparticle docetaxel formulation in breast cancer","volume":"29","author":"Kim T.H","year":"2018","unstructured":"Kim T.H., Gwak G., Chung M.S., Kim J.I., Park I., Um E., Han J.W., Lee A. (2018) Multicenter trial for safety and toxicity of a nanoparticle docetaxel formulation in breast cancer. Ann. Oncol. 29: ix3.","journal-title":"Ann. Oncol"},{"issue":"6","key":"ref-1360965","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12272-018-1008-4","article-title":"Recent progress in dendrimer-based nanomedicine development","volume":"41","author":"Kim Y","year":"2018","unstructured":"Kim Y., Park E.J., Na D.H. (2018) Recent progress in dendrimer-based nanomedicine development. Arch. Pharm. Res. 41(6): 571\u2013582.","journal-title":"Arch. Pharm. Res"},{"issue":"2","key":"ref-1360966","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.molonc.2012.02.005","article-title":"Molecular imaging for personalized cancer care","volume":"6","author":"Kircher M.F","year":"2012","unstructured":"Kircher M.F., Hricak H., Larson S.M. (2012) Molecular imaging for personalized cancer care. Mol. Oncol. 6(2): 182\u2013195.","journal-title":"Mol. Oncol"},{"issue":"3","key":"ref-1360967","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijrobp.2022.06.089","article-title":"Nab-paclitaxel, capecitabine, and radiation therapy after induction chemotherapy in treating patients with locally advanced and borderline resectable pancreatic cancer: phase 1 trial and imaging-based biomarker validation","volume":"114","author":"Koay E.J","year":"2022","unstructured":"Koay E.J., Zaid M., Aliru M., Bagereka P., Van Wieren A., Rodriguez M.J., et al. (2022) Nab-paclitaxel, capecitabine, and radiation therapy after induction chemotherapy in treating patients with locally advanced and borderline resectable pancreatic cancer: phase 1 trial and imaging-based biomarker validation. Int. J. Radiat. Oncol. Biol. Phys. 114(3): 444\u2013453.","journal-title":"Int. J. Radiat. Oncol. Biol. Phys"},{"key":"ref-1360968","first-page":"1","article-title":"Synthesis, properties, and applications of magnetic nanoparticles for cancer therapy: a review","volume":"23","author":"Kumar A","year":"2021","unstructured":"Kumar A., Chander N., Lee J., Kim K. (2021) Synthesis, properties, and applications of magnetic nanoparticles for cancer therapy: a review. J. Nanopart. Res. 23: 1\u201324.","journal-title":"J. Nanopart. Res"},{"issue":"10152","key":"ref-1360969","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(18)32252-9","article-title":"GLOBOCAN 2018: counting the toll of cancer","volume":"392","author":"Lancet T","year":"2018","unstructured":"Lancet T. (2018) GLOBOCAN 2018: counting the toll of cancer. Lancet (London, England) 392(10152): 985.","journal-title":"Lancet (London, England"},{"key":"ref-1360970","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ijbiomac.2021.12.052","article-title":"Nanotechnology-based approaches for effective detection of tumor markers: a comprehensive state-of-the-art review","volume":"195","author":"Laraib U","year":"2022","unstructured":"Laraib U., Sargazi S., Rahdar A., Khatami M., Pandey S. (2022) Nanotechnology-based approaches for effective detection of tumor markers: a comprehensive state-of-the-art review. Int. J. Biol. Macromol. 195: 356\u2013383.","journal-title":"Int. J. Biol. Macromol"},{"issue":"7","key":"ref-1360971","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41571-023-00781-y","article-title":"Circulating tumour cells for early detection of clinically relevant cancer","volume":"20","author":"Lawrence R","year":"2023","unstructured":"Lawrence R., Watters M., Davies C.R., Pantel K., Lu Y.J. (2023) Circulating tumour cells for early detection of clinically relevant cancer. Nat. Rev. Clin. Oncol. 20(7): 487\u2013500.","journal-title":"Nat. Rev. Clin. Oncol"},{"issue":"16","key":"ref-1360972","doi-asserted-by":"crossref","first-page":"12682","DOI":"10.3390\/ijms241612682","article-title":"Current advances in the biomedical applications of quantum dots: promises and challenges","volume":"24","author":"Le N","year":"2023","unstructured":"Le N., Kim K. (2023) Current advances in the biomedical applications of quantum dots: promises and challenges. Int. J. Mol. Sci. 24(16): 12682.","journal-title":"Int. J. Mol. Sci"},{"key":"ref-1360973","doi-asserted-by":"crossref","first-page":"e16257","DOI":"10.1200\/JCO.2023.41.16_suppl.e16257","article-title":"Phase 2 study of weekly polymeric micelle-formulated paclitaxel plus gemcitabine in patients with recurrent and metastatic adenocarcinoma of the pancreas","volume":"41","author":"Lee H.W","year":"2023","unstructured":"Lee H.W., Kang S.Y., Kim I.H., Sun D.S., An H.J., Jang J.S., et al. (2023) Phase 2 study of weekly polymeric micelle-formulated paclitaxel plus gemcitabine in patients with recurrent and metastatic adenocarcinoma of the pancreas. J. Clin. Oncol. 41(16_suppl): e16257-e16257","journal-title":"J. Clin. Oncol"},{"key":"ref-1360974","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10549-007-9591-y","article-title":"Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer","volume":"108","author":"Lee K.S","year":"2008","unstructured":"Lee K.S., Chung H.C., Im S.A., Park Y.H., Kim C.S., Kim S.B., et al. (2008) Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res. Treat. 108: 241\u2013250.","journal-title":"Breast Cancer Res. Treat"},{"key":"ref-1360975","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.biomaterials.2015.10.046","article-title":"Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles","volume":"76","author":"Li J","year":"2016","unstructured":"Li J., Ai Y., Wang L., Bu P., Sharkey C.C., Wu Q., et al. (2016) Targeted drug delivery to circulating tumor cells via platelet membrane-functionalized particles. Biomaterials 76: 52\u201365.","journal-title":"Biomaterials"},{"issue":"32","key":"ref-1360976","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1002\/adma.201300875","article-title":"Smart drug delivery nanocarriers with self assembled DNA nanostructures","volume":"25","author":"Li J","year":"2013","unstructured":"Li J., Fan C., Pei H., Shi J., Huang Q. (2013) Smart drug delivery nanocarriers with self assembled DNA nanostructures. Adv. Mater. 25(32): 4386\u20134396.","journal-title":"Adv. Mater"},{"issue":"9","key":"ref-1360977","first-page":"1269","article-title":"Albumin-based nanoparticles as a controlled release system for delivering paclitaxel","volume":"53","author":"Li W","year":"2015","unstructured":"Li W., Zheng C., Pan Y., Wang X., Wang P., Zhang Y., Shi W. (2015) Albumin-based nanoparticles as a controlled release system for delivering paclitaxel. Pharmaceut. Biol. 53(9): 1269\u20131275.","journal-title":"Pharmaceut. Biol"},{"issue":"9","key":"ref-1360978","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1039\/D0NR08050K","article-title":"Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages","volume":"13","author":"Li X","year":"2021","unstructured":"Li X., Guo X., Ling J., Tang Z., Huang G., He L., Chen T. (2021) Nanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages. Nanoscale 13(9): 4705\u20134727.","journal-title":"Nanoscale"},{"issue":"18","key":"ref-1360979","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1080\/14656566.2023.2269086","article-title":"Liposomal drug formulations for the treatment of hematological malignancies","volume":"24","author":"Limi D.C","year":"2023","unstructured":"Limi D.C., Reikvam H. (2023) Liposomal drug formulations for the treatment of hematological malignancies. Exp. Opin. Pharmacother. 24(18): 1911\u20131914.","journal-title":"Exp. Opin. Pharmacother"},{"key":"ref-1360980","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.tibtech.2015.08.001","article-title":"DNA nanostructures as smart drug-delivery vehicles and molecular devices","volume":"33","author":"Linko V","year":"2015","unstructured":"Linko V., Ora A., Kostiainen M.A. (2015) DNA nanostructures as smart drug-delivery vehicles and molecular devices. Trends Biotechnol. 33: 586\u2013594.","journal-title":"Trends Biotechnol"},{"key":"ref-1360981","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.biomaterials.2012.12.038","article-title":"The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEI-PEG based nanoparticles","volume":"34","author":"Liu C","year":"2013","unstructured":"Liu C., Liu F., Feng L., Li M., Zhang J., Zhang N. (2013) The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEI-PEG based nanoparticles. Biomaterials 34: 2547\u20132564.","journal-title":"Biomaterials"},{"issue":"10","key":"ref-1360982","first-page":"1231","article-title":"Aptamer-assisted delivery of chemotherapeutic drugs for cancer treatment","volume":"13","author":"Liu J","year":"2018","unstructured":"Liu J., Wang C., Wang X., et al. (2018) Aptamer-assisted delivery of chemotherapeutic drugs for cancer treatment. Nanomedicine 13(10): 1231\u20131246.","journal-title":"Nanomedicine"},{"issue":"1","key":"ref-1360983","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4155\/tde-2020-0079","article-title":"Challenges and opportunities in the delivery of cancer therapeutics: update on recent progress","volume":"12","author":"Lorscheider M","year":"2021","unstructured":"Lorscheider M., Gaudin A., Nakhl\u00e9 J., Veiman K. L., Richard J., Chassaing C. (2021) Challenges and opportunities in the delivery of cancer therapeutics: update on recent progress. Ther. Deliv. 12(1): 55\u201376.","journal-title":"Ther. Deliv"},{"issue":"1","key":"ref-1360984","first-page":"16","article-title":"Recent advances in gold nanoparticle-based contrast agents for computed tomography imaging","volume":"9","author":"Ma X","year":"2021","unstructured":"Ma X., Zhao Y., Liang X., Wang L., Jiang H. (2021) Recent advances in gold nanoparticle-based contrast agents for computed tomography imaging. J. Mater. Chem. B. 9(1): 16\u201336.","journal-title":"J. Mater. Chem. B"},{"key":"ref-1360985","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda H","year":"2013","unstructured":"Maeda H., Nakamura H., Fang J. (2013) The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev. 65: 71\u201379.","journal-title":"Adv. Drug Deliv. Rev"},{"issue":"2","key":"ref-1360986","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1021\/cr1001832","article-title":"Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine","volume":"111","author":"Mahmoudi M","year":"2011","unstructured":"Mahmoudi M., Hosseinkhani H., Hosseinkhani M., Boutry S., Simchi A., Journeay W. S., Laurent S. (2011) Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine. Chem. Rev. 111(2): 253\u2013280.","journal-title":"Chem. Rev"},{"key":"ref-1360987","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11060-010-0389-0","article-title":"Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme","volume":"103","author":"Maier-Hauff K","year":"2011","unstructured":"Maier-Hauff K., Ulrich F., Nestler D., Niehoff H., Wust P., Thiesen B., et al. (2011) Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J. Neurooncol. 103: 317\u2013324.","journal-title":"J. Neurooncol"},{"issue":"2","key":"ref-1360988","doi-asserted-by":"crossref","first-page":"179","DOI":"10.21037\/tau-21-723","article-title":"ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD\u00ae) in Asian men with prostate cancer","volume":"11","author":"Malek R","year":"2022","unstructured":"Malek R., Wu S.T., Serrano D., Tho T., Umbas R., Teoh J., et al. (2022) ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD\u00ae) in Asian men with prostate cancer. Transl. Androl. Urol. 11(2): 179.","journal-title":"Transl. Androl. Urol"},{"key":"ref-1360989","first-page":"1","volume-title":"Nanomaterials for biosensors","author":"Malhotra B.D","year":"2018","unstructured":"Malhotra B.D., Ali M.A. (2018) Nanomaterials in biosensors: fundamentals and applications. [in:] Nanomaterials for biosensors. Elsevier: 1\u201374."},{"issue":"4","key":"ref-1360990","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1021\/acsnano.8b00940","article-title":"Prostate-specific membrane antigen targeted gold nanoparticles for theranostics of prostate cancer","volume":"12","author":"Mangadlao J.D","year":"2018","unstructured":"Mangadlao J.D., Wang X., McCleese C., Escamilla M., Ramamurthy G., Wang Z., Govande M., Basilion J.P., Burda C. (2018) Prostate-specific membrane antigen targeted gold nanoparticles for theranostics of prostate cancer. ACS Nano. 12(4): 3714\u20133725.","journal-title":"ACS Nano"},{"issue":"5","key":"ref-1360991","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2174\/1871520620666200619181425","article-title":"Smart nanocarriers for targeted cancer therapy","volume":"21","author":"Martinelli C","year":"2021","unstructured":"Martinelli C. (2021) Smart nanocarriers for targeted cancer therapy. Anticancer Agents Med. Chem. 21(5): 546\u2013557.","journal-title":"Anticancer Agents Med. Chem"},{"key":"ref-1360992","doi-asserted-by":"crossref","first-page":"114628","DOI":"10.1016\/j.jpba.2022.114628","article-title":"Fluorescence sensing and imaging with carbon-based quantum dots for early diagnosis of cancer: a review","volume":"212","author":"Mohammadi R","year":"2022","unstructured":"Mohammadi R., Naderi-Manesh H., Farzin L., Vaezi Z., Ayarri N., Samandari L., et al. (2022) Fluorescence sensing and imaging with carbon-based quantum dots for early diagnosis of cancer: a review. J. Pharm. Biomed. Anal. 212: 114628.","journal-title":"J. Pharm. Biomed. Anal"},{"key":"ref-1360993","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fonc.2017.00314","article-title":"Fluorescence-guided surgery","volume":"7","author":"Nagaya T","year":"2017","unstructured":"Nagaya T., Nakamura Y.A., Choyke P.L., Kobayashi H. (2017) Fluorescence-guided surgery. Front. Oncol. 7: 314.","journal-title":"Front. Oncol"},{"issue":"15","key":"ref-1360994","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2174\/1568026621666210701144124","article-title":"Nanotechnology, a tool for diagnostics and treatment of cancer","volume":"21","author":"Nasir A","year":"2021","unstructured":"Nasir A., Khan A., Li J., Naeem M., Khalil A.A.K., Khan K., Qasim M. (2021) Nanotechnology, a tool for diagnostics and treatment of cancer. Curr. Top. Med. Chem. 21(15): 1360\u20131376.","journal-title":"Curr. Top. Med. Chem"},{"key":"ref-1360995","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3762\/bjoc.15.197","article-title":"Fluorinated azobenzenes as supramolecular halogen-bonding building blocks","volume":"15","author":"Nieland E","year":"2019","unstructured":"Nieland E., Weingart O., Schmidt B.M. (2019) Fluorinated azobenzenes as supramolecular halogen-bonding building blocks. Beilstein J. Org. Chem. 15: 2013\u20132019.","journal-title":"Beilstein J. Org. Chem"},{"key":"ref-1360996","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.colsurfb.2015.09.034","article-title":"Design of liposomal formulations for cell targeting","volume":"136","author":"Nogueira E","year":"2015","unstructured":"Nogueira E., Gomes A.C., Preto A., Cavaco-Paulo A. (2015) Design of liposomal formulations for cell targeting. Colloids Surf. B Biointerfaces 136: 514\u2013526.","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"12","key":"ref-1360997","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1099\/jgv.0.000641","article-title":"Simian immunodeficiency virus SIV-mac239 infection and simian human immunodeficiency virus SHIV89.6P infection result in progression to AIDS in cynomolgus macaques of Asian origin","volume":"97","author":"Okamura T","year":"2016","unstructured":"Okamura T., Tsujimura Y., Soma S., Takahashi I., Matsuo K., Yasutomi Y. (2016) Simian immunodeficiency virus SIV-mac239 infection and simian human immunodeficiency virus SHIV89.6P infection result in progression to AIDS in cynomolgus macaques of Asian origin. J. Gen. Virol. 97(12): 3413\u20133426.","journal-title":"J. Gen. Virol"},{"issue":"3","key":"ref-1360998","doi-asserted-by":"crossref","first-page":"569","DOI":"10.4143\/crt.2016.289","article-title":"An open-label, randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric micelle-formulated paclitaxel compared to conventional cremophor EL-based paclitaxel for recurrent or metastatic HER2-negative breast cancer","volume":"49","author":"Park I.H","year":"2017","unstructured":"Park I.H., Sohn J.H., Kim S.B., Lee K.S., Chung J.S., Lee S.H., et al. (2017) An open-label, randomized, parallel, phase III trial evaluating the efficacy and safety of polymeric micelle-formulated paclitaxel compared to conventional cremophor EL-based paclitaxel for recurrent or metastatic HER2-negative breast cancer. Cancer Res. Treat. 49(3): 569.","journal-title":"Cancer Res. Treat"},{"key":"ref-1360999","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra J.K","year":"2018","unstructured":"Patra J.K., Das G., Fraceto L.F., Campos E.V.R., Rodriguez-Torres M.D.P., Acosta-Torres L.S., et al. (2018) Nano based drug delivery systems: recent developments and future prospects. J. Nanobiotechnol. 16: 1\u201333.","journal-title":"J. Nanobiotechnol"},{"key":"ref-1361000","first-page":"94","article-title":"Dendritic polymer macromolecular carriers for drug delivery","volume":"28","author":"Patri A.K","year":"2015","unstructured":"Patri A.K., Majoros Jr I.J., Baker Jr J.R. (2015) Dendritic polymer macromolecular carriers for drug delivery. Curr. Opin. Chem. Biol. 28: 94\u2013104.","journal-title":"Curr. Opin. Chem. Biol"},{"issue":"9","key":"ref-1361001","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1021\/acs.bioconjchem.9b00456","article-title":"Insights into active targeting of nanoparticles in drug delivery: advances in clinical studies and design considerations for cancer nanomedicine","volume":"30","author":"Pearce A.K","year":"2019","unstructured":"Pearce A.K., O\u2019Reilly R.K. (2019) Insights into active targeting of nanoparticles in drug delivery: advances in clinical studies and design considerations for cancer nanomedicine. Bioconjug. Chem. 30(9): 2300\u20132311.","journal-title":"Bioconjug. Chem"},{"key":"ref-1361002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1201\/9780429399039-2","volume-title":"Nano-enabled medical applications","author":"Peer D","year":"2020","unstructured":"Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. (2020) Nanocarriers as an emerging platform for cancer therapy. [in:] Nano-enabled medical applications. Jenny Stanford Publ.: 61\u201391."},{"issue":"10","key":"ref-1361003","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/bjc.2017.67","article-title":"Quality-adjusted survival with combination nal-IRI+ 5-FU\/LV vs 5-FU\/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis","volume":"116","author":"Pelzer U","year":"2017","unstructured":"Pelzer U., Blanc J.F., Melisi D., Cubillo A., Von Hoff D.D., Wang-Gillam A., et al. (2017) Quality-adjusted survival with combination nal-IRI+ 5-FU\/LV vs 5-FU\/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. Br. J. Cancer 116(10): 1247\u20131253.","journal-title":"Br. J. Cancer"},{"key":"ref-1361004","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy","volume":"93","author":"P\u00e9rez-Herrero E","year":"2015","unstructured":"P\u00e9rez-Herrero E., Fern\u00e1ndez-Medarde A. (2015) Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 93: 52\u201379.","journal-title":"Eur. J. Pharm. Biopharm"},{"issue":"11","key":"ref-1361005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/chemosensors9110299","article-title":"The challenges of developing biosensors for clinical assessment: a review","volume":"9","author":"Prabowo B.A","year":"2021","unstructured":"Prabowo B.A., Cabral P.D., Freitas P., Fernandes E. (2021) The challenges of developing biosensors for clinical assessment: a review. Chemosensors 9(11): 299.","journal-title":"Chemosensors"},{"key":"ref-1361006","first-page":"299","volume-title":"Nanofabrication handbook","author":"Reif J.H","year":"2012","unstructured":"Reif J.H., Chandran H., Gopalkrishnan N., LaBean T. (2012) Self-assembled DNA nanostructures and DNA devices. [in:] Nanofabrication handbook : 299\u2013328. https:\/\/doi.org\/10.1201\/b11626"},{"key":"ref-1361007","doi-asserted-by":"crossref","first-page":"119482","DOI":"10.1016\/j.ijpharm.2020.119482","article-title":"Enhanced absorption, and efficacy of oral self-assembled paclitaxel nanocochleates in multi-drug resistant colon cancer","volume":"586","author":"Shanmugam T","year":"2020","unstructured":"Shanmugam T., Joshi N., Ahamad N., Deshmukh A., Banerjee R. (2020) Enhanced absorption, and efficacy of oral self-assembled paclitaxel nanocochleates in multi-drug resistant colon cancer. Int. J. Pharm. 586: 119482.","journal-title":"Int. J. Pharm"},{"issue":"1","key":"ref-1361008","doi-asserted-by":"crossref","first-page":"012002","DOI":"10.1088\/1748-605X\/ac41fd","article-title":"Biosensors and nanotechnology for cancer diagnosis (lung and bronchus, breast, prostate, and colon): a systematic review","volume":"17","author":"Sharifianjazi F","year":"2021","unstructured":"Sharifianjazi F., Rad A.J., Bakhtiari A., Niazvand F., Esmaeilkhanian A., Bazli L., et al. (2021) Biosensors and nanotechnology for cancer diagnosis (lung and bronchus, breast, prostate, and colon): a systematic review. Biomed. Mater. 17(1): 012002.","journal-title":"Biomed. Mater"},{"key":"ref-1361009","first-page":"102545","article-title":"Gold nanoparticles as therapeutic agents in cancer: current status and future perspectives","volume":"64","author":"Sharma G","year":"2021","unstructured":"Sharma G., Kumar A., Sharma A., Naushad M., Pathania D. (2021) Gold nanoparticles as therapeutic agents in cancer: current status and future perspectives. J. Drug Deliv. Sci. Technol. 64: 102545.","journal-title":"J. Drug Deliv. Sci. Technol"},{"issue":"2","key":"ref-1361010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jss.2014.07.028","article-title":"In vivo lymph node mapping by Cadmium Tellurium quantum dots in rats","volume":"192","author":"Si C","year":"2014","unstructured":"Si C., Zhang Y., Lv X., Yang W., Ran Z., Sun P. (2014) In vivo lymph node mapping by Cadmium Tellurium quantum dots in rats. J. Surg. Res. 192(2): 305\u2013311.","journal-title":"J. Surg. Res"},{"key":"ref-1361011","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nnano.2015.180","article-title":"Designing DNA nanodevices for compatibility with the immune system of higher organisms","volume":"10","author":"Surana S","year":"2015","unstructured":"Surana S., Shenoy A.R., Krishnan Y. (2015) Designing DNA nanodevices for compatibility with the immune system of higher organisms. Nat. Nanotechnol. 10: 741\u2013747.","journal-title":"Nat. Nanotechnol"},{"issue":"10","key":"ref-1361012","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3109\/1061186X.2011.622404","article-title":"Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA","volume":"19","author":"Taratula O","year":"2011","unstructured":"Taratula O., Garbuzenko O. B., Chen A. M., Minko T., Xia Y. (2011) Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J. Drug Target. 19(10): 900\u2013914.","journal-title":"J. Drug Target"},{"issue":"2","key":"ref-1361013","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/14737140.2.2.143","article-title":"Caelyx\/Doxil for the treatment of metastatic ovarian and breast cancer","volume":"2","author":"Tejada-Berges T","year":"2002","unstructured":"Tejada-Berges T., Granai C.O., Gordinier M., Gajewski W. (2002) Caelyx\/Doxil for the treatment of metastatic ovarian and breast cancer. Exp. Rev. Anticancer Ther. 2(2): 143\u2013150.","journal-title":"Exp. Rev. Anticancer Ther"},{"issue":"1","key":"ref-1361014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40169-017-0175-0","article-title":"Cancer nanomedicine: a review of recent success in drug delivery","volume":"6","author":"Tran S","year":"2017","unstructured":"Tran S., DeGiovanni P.J., Piel B., Rai P. (2017) Cancer nanomedicine: a review of recent success in drug delivery. Clin. Transl. Med. 6(1): 44.","journal-title":"Clin. Transl. Med"},{"issue":"3","key":"ref-1361015","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3109\/02656736.2014.913321","article-title":"Magnetic resonance imaging contrast of iron oxide nanoparticles developed for hyperthermia is dominated by iron content","volume":"30","author":"Wabler M","year":"2014","unstructured":"Wabler M., Zhu W., Hedayati M., Attaluri A., Zhou H., Mihalic J., Geyh A., DeWeese T.L., Ivkov R., Artemov D. (2014). Magnetic resonance imaging contrast of iron oxide nanoparticles developed for hyperthermia is dominated by iron content. Int. J. Hyperther. 30(3): 192\u2013200.","journal-title":"Int. J. Hyperther"},{"issue":"12","key":"ref-1361016","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1080\/03639045.2016.1185435","article-title":"RGD peptide targeted lipid-coated nanoparticles for combinatorial delivery of sorafenib and quercetin against hepatocellular carcinoma","volume":"42","author":"Wang C","year":"2016","unstructured":"Wang C., Su L., Wu C., Wu J., Zhu C., Yuan G. (2016) RGD peptide targeted lipid-coated nanoparticles for combinatorial delivery of sorafenib and quercetin against hepatocellular carcinoma. Drug Dev. Ind. Pharm. 42(12): 1938\u20131944.","journal-title":"Drug Dev. Ind. Pharm"},{"key":"ref-1361017","first-page":"442","article-title":"Magnetic nanoparticles for enhanced cancer diagnosis and therapy","volume":"26","author":"Wang H","year":"2018","unstructured":"Wang H., Liu K., Chen Y., Liang X., Chen Q. (2018) Magnetic nanoparticles for enhanced cancer diagnosis and therapy. J. Drug Target. 26: 442\u2013448.","journal-title":"J. Drug Target"},{"key":"ref-1361018","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fphar.2018.00202","article-title":"Poly(ethylene glycol)\u2013polylactide micelles for cancer therapy","volume":"9","author":"Wang J","year":"2018","unstructured":"Wang J., Li S., Han Y., Guan J., Chung S., Wang C., Li D. (2018) Poly(ethylene glycol)\u2013polylactide micelles for cancer therapy. Front. Pharmacol. 9: 202.","journal-title":"Front. Pharmacol"},{"key":"ref-1361019","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.colsurfb.2017.11.013","article-title":"Delivery of paclitaxel using nanoparticles composed of poly(ethylene oxide)-b-poly(butylene oxide) (PEO-PBO)","volume":"161","author":"Wang L","year":"2018","unstructured":"Wang L., Yao J., Zhang X., Zhang Y., Xu C., Lee R.J., Yu G., Yu B., Teng L. (2018) Delivery of paclitaxel using nanoparticles composed of poly(ethylene oxide)-b-poly(butylene oxide) (PEO-PBO). Colloids Surf. B Biointerfaces 161: 464\u2013470.","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"1","key":"ref-1361020","first-page":"1330414","article-title":"Using liposomes as carriers for biomedical applications","volume":"8","author":"Wang Y","year":"2017","unstructured":"Wang Y., Yang T., Ke H., Zhu A., Wang Y., Wang J., Ge Z. (2017) Using liposomes as carriers for biomedical applications. Nano Rev. Exp. 8(1): 1330414.","journal-title":"Nano Rev. Exp"},{"key":"ref-1361021","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1007\/s11095-011-0604-5","article-title":"RNA interference and cancer therapy","volume":"28","author":"Wang Z","year":"2011","unstructured":"Wang Z., Rao D.D., Senzer N., Nemunaitis J. (2011) RNA interference and cancer therapy. Pharm. Res. 28: 2983\u20132995.","journal-title":"Pharm. Res"},{"issue":"5","key":"ref-1361022","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumors","volume":"1","author":"Wilhelm S","year":"2016","unstructured":"Wilhelm S., Tavares A.J., Dai Q., Ohta S., Audet J., Dvorak H.F., Chan W.C. (2016) Analysis of nanoparticle delivery to tumors. Nat. Rev. Mater. 1(5): 16014.","journal-title":"Nat. Rev. Mater"},{"issue":"16","key":"ref-1361023","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1039\/D0CS01370F","article-title":"Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies","volume":"50","author":"Xie J","year":"2021","unstructured":"Xie J., Wang Y., Choi W., Jangili P., Ge Y., Xu Y., Kang J., Liu L., Zhang B., Xie Z., He J. (2021) Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies. Chem. Soc. Rev. 50(16): 9152\u20139201.","journal-title":"Chem. Soc. Rev"},{"issue":"8","key":"ref-1361024","first-page":"763","article-title":"Folate-functionalized gold nanoparticles for cancer therapy: in vitro and in vivo studies","volume":"20","author":"Xiong Y","year":"2012","unstructured":"Xiong Y., Zhang Y., Wu S. (2012) Folate-functionalized gold nanoparticles for cancer therapy: in vitro and in vivo studies. J. Drug. Target. 20(8): 763\u2013771.","journal-title":"J. Drug. Target"},{"issue":"1","key":"ref-1361025","first-page":"84","article-title":"Doxorubicin, DNA torsion, and chromatin dynamics","volume":"1845","author":"Yang F","year":"2014","unstructured":"Yang F., Teves S.S., Kemp C.J., Henikoff S. (2014) Doxorubicin, DNA torsion, and chromatin dynamics. Biochim. Biophys. Acta 1845(1): 84\u201389.","journal-title":"Biochim. Biophys. Acta"},{"key":"ref-1361026","doi-asserted-by":"crossref","first-page":"1249875","DOI":"10.3389\/fbioe.2023.1249875","article-title":"Nanotechnology boosts the efficiency of tumor diagnosis and therapy","volume":"11","author":"Yang Y","year":"2023","unstructured":"Yang Y., Lin M., Sun M., Zhang G.Q., Guo J., Li J. (2023) Nanotechnology boosts the efficiency of tumor diagnosis and therapy. Front. Bioeng. Biotechnol. 11: 1249875.","journal-title":"Front. Bioeng. Biotechnol"},{"issue":"3","key":"ref-1361027","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/nnm-2018-0414","article-title":"Hybrid quantum dot-based theranostic nanomedicines for tumor-targeted drug delivery and cancer imaging","volume":"14","author":"Zayed D.G","year":"2019","unstructured":"Zayed D.G., AbdElhamid A.S., Freag M.S., Elzoghby A.O. (2019) Hybrid quantum dot-based theranostic nanomedicines for tumor-targeted drug delivery and cancer imaging. Nanomedicine 14(3): 225\u2013228.","journal-title":"Nanomedicine"},{"key":"ref-1361028","doi-asserted-by":"crossref","first-page":"e58037","DOI":"10.1371\/journal.pone.0058037","article-title":"Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer","volume":"8","author":"Zhang C","year":"2013","unstructured":"Zhang C., Awasthi N., Schwarz M.A., Hinz S., Schwarz R.E. (2013) Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. PLoS One 8: e58037.","journal-title":"PLoS One"},{"issue":"13","key":"ref-1361029","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1039\/D0BM00679C","article-title":"Boronic acid-engineered gold nanoparticles for cytosolic protein delivery","volume":"8","author":"Zhang S","year":"2020","unstructured":"Zhang S., Cheng Y. (2020) Boronic acid-engineered gold nanoparticles for cytosolic protein delivery. Biomater. Sci. 8(13): 3741\u20133750.","journal-title":"Biomater. Sci"},{"key":"ref-1361030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0833-3","article-title":"Nanotechnology in cancer diagnosis: progress, challenges and opportunities","volume":"12","author":"Zhang Y","year":"2019","unstructured":"Zhang Y., Li M., Gao X., Chen Y., Liu T. (2019) Nanotechnology in cancer diagnosis: progress, challenges and opportunities. J. Hematol. Oncol. 12: 1\u201313.","journal-title":"J. Hematol. Oncol"},{"key":"ref-1361031","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/IJN.S37859","article-title":"Molecular targeting of liposomal nanoparticles to tumor microenvironment","volume":"8","author":"Zhao G","year":"2012","unstructured":"Zhao G., Rodriguez B.L. (2012) Molecular targeting of liposomal nanoparticles to tumor microenvironment. Int. J. Nanomedicine 8: 61\u201371.","journal-title":"Int. J. Nanomedicine"},{"key":"ref-1361032","first-page":"1","article-title":"Application of functional quantum dot nanoparticles as fluorescence probes in cell labeling and tumor diagnostic imaging","volume":"10","author":"Zhao M.X","year":"2015","unstructured":"Zhao M.X., Zeng E.Z. (2015) Application of functional quantum dot nanoparticles as fluorescence probes in cell labeling and tumor diagnostic imaging. Nanoscale Res. Lett. 10: 1\u20139.","journal-title":"Nanoscale Res. Lett"},{"issue":"1","key":"ref-1361033","first-page":"1","article-title":"Gold nanoparticles-based optical imaging and therapy for cancer","volume":"18","author":"Zhao Z","year":"2020","unstructured":"Zhao Z., Zhang M., Wen L., Zhang W., Chen G. (2020) Gold nanoparticles-based optical imaging and therapy for cancer. J. Nanobiotechnol. 18(1): 1\u201317.","journal-title":"J. Nanobiotechnol"}],"container-title":["BioTechnologia"],"original-title":[],"link":[{"URL":"https:\/\/www.termedia.pl\/doi_ft\/10.5114\/bta.2024.141807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T12:00:36Z","timestamp":1741348836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biotechnologia-journal.org\/Nanotechnology-in-cancer-therapeutics-diagnosis-r-nand-management,190888,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"alternative-id":["190888"],"URL":"https:\/\/doi.org\/10.5114\/bta.2024.141807","relation":{},"ISSN":["0860-7796","2353-9461"],"issn-type":[{"value":"0860-7796","type":"print"},{"value":"2353-9461","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]}}}